TO THE STRATEGIC COLLABORATION, OPTION AND LICENSE AGREEMENTStrategic Collaboration, Option and License Agreement • February 15th, 2018 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations • Massachusetts
This Amendment No. 1 to the Strategic Collaboration, Option and License Agreement, dated October 26, 2015, between Vertex Pharmaceuticals Incorporated (“ Vertex Parent ”) and Vertex Pharmaceuticals (Europe) Limited (“ Vertex UK ” and together with Vertex Parent, “ Vertex ”), on the one hand, and CRISPR Therapeutics AG (“ CRISPR AG ”), CRISPR Therapeutics, Inc. (“ CRISPR Inc. ”), CRISPR Therapeutics Limited (“ CRISPR UK ”) and TRACR Hematology Ltd (“ Tracr ” and together with CRISPR AG, CRISPR Inc. and CRISPR UK “ CRISPR ”), on the other hand (this “ Amendment ”) is entered into as of this 12th day of December, 2017 (the “ Amendment Effective Date ”) by and between Vertex and CRISPR. Capitalized terms used and not defined herein have their respective meanings set forth in the Agreement (as defined below).
